Whose Responsibility Are Ethical Issues in Phase 1 Research?

April 12, 2023 · by · in Human Rights, Law & Policy, Pharmaceuticals, Research Ethics, Social Justice

Dessislava Fessenko reveals that ethical concerns surrounding the participation of healthy volunteers in Phase 1 clinical trials have deep roots in broader social conditions, which require social policy responses.

Human Genome Editing: From the First to the Third International Summit

March 22, 2023 · by · in Law & Policy, Reproduction, Research Ethics, Science and Technology

Françoise Baylis discusses the outcome of the Third International Summit on Human Genome Editing.

COVID-19 Vaccine Certification: A Contentious Proposal

January 8, 2021 · by · in Canada, Community, Coronavirus, COVID-19, Law & Policy, Pandemic, Pharmaceuticals, Science and Technology, Social Justice, Vaccine, vulnerability

Françoise Baylis highlights some of the limitations of COVID-19 vaccine certificates.

MAiD for mental suffering: The limits of psychiatry

September 17, 2020 · by · in Clinical Ethics, Death & Assisted Dying, Law & Policy, MAiD, Mental Health, physician-assisted dying, vulnerability

Peter J. Baylis critiques the argument that mental health concerns are never irremediable, and that people with a mental illness as a sole underlying condition should not be eligible for medical assistance in dying.

Reopening Canada while protecting public health

June 1, 2020 · by · in Canada, Canadian Bioethics, Community, Coronavirus, COVID-19, Global Health, Inclusivity, Law & Policy, vulnerability

Natalie Kofler and Françoise Baylis remind us that everyone must be protected during this pandemic.

← Older posts